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Abstract
Myxoma virus (MYXV)-encoded protein M029 is a member of the poxvirus E3 family of dsRNA-binding proteins that
antagonize the cellular interferon signaling pathways. In order to investigate additional functions of M029, we have
constructed a series of targeted M029-minus (vMyx-M029KO and vMyx-M029ID) and V5-tagged M029 MYXV. We found that
M029 plays a pivotal role in determining the cellular tropism of MYXV in all mammalian cells tested. The M029-minus viruses
were able to replicate only in engineered cell lines that stably express a complementing protein, such as vaccinia E3, but
underwent abortive or abated infection in all other tested mammalian cell lines. The M029-minus viruses were dramatically
attenuated in susceptible host European rabbits and caused no observable signs of myxomatosis. Using V5-tagged M029
virus, we observed that M029 expressed as an early viral protein is localized in both the nuclear and cytosolic compartments
in virus-infected cells, and is also incorporated into virions. Using proteomic approaches, we have identified Protein Kinase R
(PKR) and RNA helicase A (RHA)/DHX9 as two cellular binding partners of M029 protein. In virus-infected cells, M029
interacts with PKR in a dsRNA-dependent manner, while binding with DHX9 was not dependent on dsRNA. Significantly,
PKR knockdown in human cells rescued the replication defect of the M029-knockout viruses. Unexpectedly, this rescue of
M029-minus virus replication by PKR depletion could then be reversed by RHA/DHX9 knockdown in human monocytic
THP1 cells. This indicates that M029 not only inhibits generic PKR anti-viral pathways, but also binds and conscripts RHA/
DHX9 as a pro-viral effector to promote virus replication in THP1 cells. Thus, M029 is a critical host range and virulence factor
for MYXV that is required for replication in all mammalian cells by antagonizing PKR-mediated anti-viral functions, and also
conscripts pro-viral RHA/DHX9 to promote viral replication specifically in myeloid cells.
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Introduction
Poxviruses encode dozens of modulatory proteins that are
involved in evasion of host immune responses and are critical
virulence factors needed for viral pathogenesis [1,2,3]. The
poxvirus E3 family of immune evasion proteins antagonizes
multiple anti-viral cellular signaling pathways that are primarily
induced by interferon (IFN). The two best-characterized cellular
targets of the E3 protein, encoded by the vaccinia virus (VACV)
E3L gene, are PKR and 29-59-oligoadenylate synthetase (29-
59OAS), both of which are activated by dsRNA and trigger a
global inhibition of protein synthesis to combat progression of the
viral replication cycle [4,5,6,7]. VACV E3 also blocks the
activation of IFN regulatory transcription factors 3 (IRF-3) and
7 (IRF-7) [8], nuclear factor kB (NF-kB) [9,10], and IFN-
stimulated gene 15 (ISG15) [11], all of which contribute to the
anti-viral state of IFN-treated cells. This subversion of host anti-
viral functions by VACV E3 is primarily mediated by at least two
protein domains: a carboxy (C)-terminal dsRNA-binding domain
and an amino (N)-terminal Z-DNA binding domain [12,13,14,15],
both of which are required for full virus virulence in mice.
Targeted deletion of the E3L gene of VACV results in reduced
cellular tropism in certain cultured cell lines and increased
sensitivity to the inhibitory effects of IFNs [16]. However, the in
vitro and in vivo roles of the two N- and C- terminal domains of E3
differ significantly, for reasons not yet clearly defined. For
example, the N-terminal domain of E3 is not required for VACV
replication in at least some cell types, but is required for in vivo
pathogenicity [13,14,17]. In addition, the N–terminal domain is
required for inhibition of the type I IFN response in mice and in
mouse embryo fibroblasts (MEFs) [15]. More recent studies
suggest that E3 also plays a role in antagonizing the cellular
sensing pathways activated by dsDNA and dsRNAs as mediated
by various cellular PRRs [18,19,20].
Several studies indicate that E3 function(s) in VACV can be
complemented in vitro, but not in vivo, by various related viral and
bacterial proteins with dsRNA-binding capacity. For example,
influenza virus NS1, reovirus S4, Escherichia coli RNase III or the
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Orf Virus E3 homologue could complement some E3 host range
functions in cultured cells but could not restore pathogenicity of
E3L-minus VACV [21,22,23,24]. This suggests that the dsRNA
binding properties of these proteins alone may not be sufficient for
rescuing VACV in vivo replication and virulence in the absence of
E3. Moreover, E3 orthologs derived from poxviruses of other
genera were also not able to restore full VACV pathogenicity in
the absence of E3 [25]. These various tested E3 orthologs were
also significantly diverged in terms of their capacity to complement
the host range functions of E3 in cultured mammalian cells. These
results all suggest that the various poxvirus E3 orthologs might
have acquired unique host immune modulatory functions and
have different cellular target(s), depending on the evolutionary
histories of the specific virus. In other words, the dsRNA-binding
property alone may not be sufficient to explain all of the many
known E3 functions.
Myxoma virus (MYXV) is a rabbit-specific Leporipoxvirus that
encodes a portfolio of immunomodulatory proteins, many of which
are very distinct from those encoded by the Orthopoxvirus VACV
[26]. Of the host-interactive modulatory proteins that are relatively
more similar between the two viruses, the MYXV M029 is a
truncated ortholog of VACV E3 that lacks a significant portion of N-
terminal Z-DNA binding domain of VACV E3 [26]. Replacement
of E3 with M029 in the VACV background can restore some of the
host range functions of E3 (for example, in HeLa cells) presumably
by suppression of common cellular anti-viral activities [25].
However, M029 replacement was not able to restore pathogenicity
of E3-deficient VACV in vivo. This suggests that, M029 likely also has
distinct roles in terms of MYXV biology, such as virus pathogenicity
in rabbits, anti-viral activity and/or host range functions.
Here we report several important and novel roles for M029 in
MYXV tropism and pathogenicity, in terms of both extending
viral host range in cultured mammalian cells, as well as acting as a
virulence factor for myxomatosis in European rabbits. When
M029 expression was abrogated, the M029-minus MYXV
constructs were defective for replication in essentially all mam-
malian cell types tested and failed to cause any aspects of
myxomatosis disease in rabbits. We exploited a proteomic
approach to reveal that M029 is a major host range determinant
for MYXV, with at least two distinct biological functions. One is to
bind PKR protein in a dsRNA-dependent fashion in order to
antagonize PKR anti-viral responses in a wide variety of
mammalian cell lineages from multiple species. M029 also
interacts with a cellular member of the DEXD/H box family of
proteins, RHA/DHX9, in a dsRNA-independent fashion. How-
ever, in contrast to PKR, instead of inhibiting this second target,
M029 binds and conscripts RHA/DHX9 to promote MYXV
replication in a cell type dependent manner. Thus, these two
distinct cellular protein interactions of M029 represent the first
example of a single viral immunomodulatory protein interacting
with two distinct host binding partners, one of which (PKR) is
inhibited to alleviate anti-viral responses and the other (RHA/
DHX9) is redeployed as a novel pro-viral effector to expand viral
tropism in a select subset of target mammalian cells.
Results
M029 is a critical host range factor for MYXV in rabbit
cells
MYXV M029 has a single predicted dsRNA-binding domain,
which displays approximately 45% sequence identity with the C-
terminal dsRNA-binding domain of VACV E3, but it lacks the
predicted N-terminal Z DNA binding motif that is found in E3. In
order to study the biological functions of M029, we have disrupted
M029 ORF by either inserting an eGFP expression cassette driven
by a poxvirus synthetic early/late promoter (pE/L) [27] within the
ORF (vMyx-M029ID) or replacing the entire M029 ORF with the
same eGFP cassette (vMyx-M029KO) (Fig. 1). However, although
we were able to detect eGFP-expressing viruses in the crude
infection/transfection mixtures used to construct these viruses, we
were not able to isolate any pure M029-defective recombinant
viruses (i.e. expressing eGFP) in rabbit RK13, primate BSC40,
hamster BHK21 or any other human cell lines that are normally
permissive for wildtype MYXV replication. Instead, cloned M029-
minus viruses were able to form foci only in engineered RK13 cell
lines that constitutively express VACV E3 (RK13-E3) alone or
expressed both E3 and K3 (RK13-E3K3) from VACV. Using these
complementing cell lines, we were able to purify both M029-
defective MYXVs, vMyx-M029KO (i.e. M029 knockout) and
vMyx-M029ID (i.e. M029 insertional disruption). Both vMyx-
M029KO and vMyx-M029ID viruses replicated normally in
RK13-E3 (Fig. 2A) and RK13-E3K3 (not shown) and yielded
progeny titers similar to control wildtype MYXV, called vMyx-GFP
(MYXV expressing an eGFP cassette located at an intergenic site
between M135 and M136, and driven by a poxvirus synthetic E/L
promoter) [27,28] as assessed by single step growth curve. These
M029-minus and M029-expressing viruses formed similarly sized
foci in RK13-E3 cells (Fig. 2D). However, in the parental RK13 cell
line both vMyx-M029KO and vMyx-M029ID viruses formed
much smaller foci, indicating a defect in virus replication and/or
spread (Fig. 2D). When analyzed by single step growth curve, the
virus titers for the M029-defective viruses were consistently lower,
with more than one log difference at 12 hpi when compared with
vMyx-GFP (Fig. 2B). This difference was accompanied by delayed
viral late protein synthesis (as detected by Serp-1 levels on Western
blots) in RK13 cells from both M029 mutant viruses (Fig. 2E,
middle panels). However, there was no difference in the synthesis or
kinetics of viral early proteins as detected by measuring M-T7
expression (Fig. 2E, top panels). In contrast, in RL5, a rabbit CD4+
T cell line, infection with either vMyx-M029KO or vMyx-M029ID
viruses were abortive compared to the control vMyx-GFP
replication (Fig. 2C). No late protein synthesis at all was detected
in RL5 cells after infection with either vMyx-M029KO or vMyx-
M029ID viruses (not shown).
Author Summary
Poxviruses exploit diverse strategies to modulate host anti-
viral responses in order to achieve broad cellular tropism
and replication. Here we report the findings that Myxoma
virus (MYXV), a rabbit-specific poxvirus, expresses a viral
protein M029 that possesses dual immunomodulatory
functions. M029 binds and inhibits the anti-viral functions
of protein kinase R (PKR) and also binds and conscripts the
pro-viral activities of another cellular protein, RNA helicase
A (RHA/DHX9), a member of the DEXD/H box family of
proteins. Engineered M029-minus MYXVs did not cause
lethal disease myxomatosis in the European rabbits. M029-
minus MYXVs were also unable to replicate in diverse
mammalian cell types, but can be rescued by knocking
down the expression of PKR. However, this rescue of
M029-minus virus replication could then be reversed by
RHA/DHX9 knockdown in human myeloid cells. These
findings reveal a novel strategy used by a single viral
immunomodulatory protein that both inhibits a host anti-
viral factor and additionally conscripting a host pro-viral
factor to expand viral tropism in a wider range of target
mammalian cells.
M029 Inhibits PKR and Conscripts RHA/DHX9
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M029 is essential for replication of MYXV in all cell lines
tested that originate from human or other non-
lagomorph sources
Although MYXV is a rabbit specific poxvirus in nature, it also
infects and replicates in a wide variety of cell lines derived from
non-rabbit species, such as human, mouse, non-human primates,
or hamster. In fact, MYXV replication is especially robust in a
wide variety of human cancer cells in vitro [29,30,31,32] or in
tumor tissues within various animal models of cancer in vivo
[33,34,35,36]. We next tested the requirement of M029 for
replication of MYXV in different cell types, from a variety of non-
rabbit species, in culture. Both vMyx-M029KO and vMyx-
M029ID viruses were unable to replicate in all human cell lines
tested (eg A549, HeLa, THP1) including all cancer cells tested (not
shown) and even in primary fibroblast cell lines GM02504
(Fig. 3A). In these human cell lines, both M029-minus virus
constructs could bind, enter and initiate the synthesis of early viral
protein (eg M-T7), however, the infection was then aborted and no
synthesis of late protein (Serp-1) could be detected (Fig. 3B, top
and middle panels). No defect in viral replication or protein
synthesis was observed when these cell lines were infected with
control vMyx-GFP (Fig. 3 A and B). This suggests that abortive
infection by M029-defective MYXV in human cells was due to
virus abort at some point between early and late protein synthesis.
A comparable abortive infection by these two M029-defective
viruses was also observed in BSC40 and NIH3T3 cell lines, which
are of nonhuman primate and mouse origins, respectively (Fig. 4A,
B and D). However, in baby hamster kidney BHK-21 cells, both
vMyx-M029KO and vMyx-M029ID viruses were able to progress
further to late stages of the viral life cycle but replicated far less
Figure 1. Construction of recombinant MYXVs. A) Construction of vMyx-M029KO virus. The M029 coding sequence was replaced by a DNA
cassette where eGFP is expressed under a poxvirus synthetic early/late promoter (sE/L). The final recombination plasmid has 59 partial M028L
sequence, eGFP and M030L sequence and was constructed by three-element recombination of the Multisite Gateway system. The revertant virus
vMyx-M029KO-Rev was constructed by replacing the eGFP cassette in the knockout virus with a plasmid having M028-M029-M030 gene sequence. B)
Construction of vMyx-M029ID virus. A DNA cassette where eGFP expressed under a poxvirus synthetic early/late promoter (sE/L) was inserted within
M029 gene for disruption of M029 ORF. The final recombination plasmid has 59 partial M028L sequence, 59 partial M029L sequence, eGFP, 39 partial
M029L sequence and M030L sequence and was constructed by three-element recombination of the Multisite Gateway system. The revertant virus
vMyx-M029ID-Rev was constructed by replacing the eGFP cassette with a plasmid having the intact M028-M029-M030 gene sequence. C)
Confirmation of purified vMyx-M029KO and vMyx-M029ID viruses. PCR using primers combination of 3 and 4 (top panel) and 1 and 2 (bottom panel)
used for viral DNA from vMyx-M029KO (lanes 2 and 3), vMyx-M029ID (lanes 4 and 5), vMyx-Lau (lane 6). Lane 1 represents known size DNA ladder.
doi:10.1371/journal.ppat.1003465.g001
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efficiently compared to vMyx-GFP infection (Fig. 4C and D). This
is likely linked to the delayed late viral protein synthesis from the
M029-defective viruses as observed by monitoring Serp-1 protein
expression (Fig. 4E top panels, compare lanes 4, 5 and 6 with 11,
12 and 13). No late protein synthesis was also observed in the
M029-defective virus infected NIH3T3 or BSC40 which are
permissive for the control vMyx-GFP virus (Fig. 4E and not
shown).
Figure 2. M029 is required for optimal MYXV replication in rabbit cells. Single step growth curves of MYXV infection in A) RK13-E3, B) RK13
and C) RL5 T lymphocytes. The indicated cells were infected with vMyx-GFP, vMyx-M029KO or vMyx-M029ID at an MOI of 5, and then cells were
collected at 0, 6, 12, 24, and 48 h p.i. The virus titers were determined in triplicate following serial dilution onto RK13-E3 cells. Data are representative
of two independent experiments. D) Fluorescence microscope images of infected RK13-E3 (top panels), RK13 (middle panels) and RL5 (bottom
panels) cells. The images were taken using an inverted fluorescence microscope using a lens with610 magnification at 48 h p.i. The cells were
infected at an MOI of 0.05 for RK13-E3 and RK13 and an MOI of 3 for RL5 with vMyx-GFP (left column), vMyx-M029KO (middle column) and vMyx-
M029ID (right column). E) Expression of viral early (M-T7) and late (Serp-1) proteins in the infected RK13 cells. RK13 cells were left uninfected (M)
(lanes 1 and 8) or were infected with vMyxGFP (lanes 2 to 7) or vMyx-M029KO (lanes 9 to 14) at an MOI of 3. Cells were collected at 1 (lanes 2 and 9), 3
(lanes 3 and 10), 8 (lanes 4 and 11), 12 (lanes 5 and 12), 24 (lanes 6 and 13) and 24a in the presence of AraC (lanes 7 and 14) h p.i. The membranes
were first probed with anti-Serp-1 antibody, stripped and probed for M-T7 and actin (loading control).
doi:10.1371/journal.ppat.1003465.g002
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M029 is expressed as an early protein, is associated with
virions and is localized in the nuclear and cytosolic
compartments in virus-infected cells
In order to investigate the biological role(s) of MYXV encoded
M029 protein, we created a recombinant MYXV expressing N-
terminal V5-tagged M029 protein, leaving expression under the
native M029 promoter (Fig. 5A). The resulting virus, vMyx-
M029V5N, was used to examine M029 protein expression,
cellular localization and cellular interactions in the virus-infected
cells. Western blot analysis of vMyx-M029V5N infected RK13
cells demonstrated that M029 is expressed early (Fig. 5B, top
panel). The treatment of infected cells with cytosine b-D-
arabinofuranoside (Ara-C) (Fig. 5B, lane 9) did not affect the
synthesis of M029, confirming that M029 is expressed as an early
gene product. Ara-C blocked the expression of late MYXV
protein Serp-1 (Fig. 5B, 3rd panel), which served as a control for
the outcome of inhibition of DNA replication. Based on the
detection of M029 protein within the first hour of infection, we
then tested whether M029 protein is associated with the input
MYXV virions. We were able to readily detect V5-tagged M029
in the purified vMyx-M029V5N virions, but not in control vMyx-
GFP virions (Fig. 4C). We then prepared core (C) and soluble
membrane (M) fractions of purified vMyx-GFP, vMyx-M029V5N,
and vMyx-M029ID viruses as previously described [37] and
assessed for the presence of V5-tagged M029 protein using anti-V5
antibody. The Western blot results indicate that M029 is
associated with both the core and membrane fractions of purified
virions (Fig. 5D), while as a fractionation control MYXV protein
Figure 3. M029 is essential for MYXV replication in diverse human cells. A) Fluorescence microscope images of infected human cell lines
A549 (top panels), THP1 (second panels), HeLa (third panels) and GM02504 (bottom panels). The images were taken using an inverted fluorescence
microscope using a lens with610 magnification at 48 h p.i. The cells were infected with vMyx-GFP (left column), vMyx-M029KO (middle column) and
vMyx-M029ID (right column). B) Expression of viral early (M-T7) and late (Serp-1) proteins in the infected A549 cells. A549 cells were left uninfected
(M) (lanes 1 and 8) or were infected with vMyxGFP (lanes 2 to 7) or vMyx-M029ID (lanes 9 to 14) at an MOI of 3. Cells were collected at 2 (lanes 2 and
9), 4 (lanes 3 and 10), 8 (lanes 4 and 11), 12 (lanes 5 and 12), 24 (lanes 6 and 13) and 24a in the presence of AraC (lanes 7 and 14) h p.i. The membranes
were first probed with anti-Serp-1 antibody, stripped and probed for M-T7 and actin (loading control).
doi:10.1371/journal.ppat.1003465.g003
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M071 (an IMV surface protein) is detected only in the membrane
fractions [38]. However, we were not able to detect any
comparable association of E3 with VACV virions and this result
is consistent with previous observations (not shown, and [39]).
We next studied the localization of M029 protein in virus-
infected cells using immunofluorescence microscopy. When RK13
cells were infected with vMyx-M029V5N at an MOI of 5 for
3 hrs, V5-tagged M029 protein was detected in both the nuclear
Figure 4. M029 is essential for MYXV replication in cell lines originated from diverse species. Single step growth curves of MYXV
infection in A) BSC40, B) NIH3T3 and C) BHK21 cells. The indicated cells were infected with vMyx-GFP, vMyx-M029KO or vMyx-M029ID at an MOI of 5,
and then cells were collected at 0, 6, 12, 24, 36, and 48 h p.i. virus titers were determined in triplicate following serial dilution onto RK13-E3 cells. Data
are representative of two independent experiments. D) Fluorescence microscope images of infected BSC40 (top panels), NIH3T3 (middle panels) and
BHK21 (bottom panels) cells. The images were taken using an inverted fluorescence microscope using a lens with610 magnification at 48 h p.i. The
cells were infected with vMyx-GFP (left column), vMyx-M029KO (middle column) and vMyx-M029ID (right column). E) Expression of viral early (M-T7)
and late (Serp-1) proteins in the infected BHK21 and NIH3T3 cells. BHK21 and NIH3T3 cells were left uninfected (M) (lanes 1 and 8) or were infected
with vMyxGFP (lanes 2 to 7) or vMyx-M029ID (lanes 9 to 14) at an MOI of 3. Cells were collected at 2 (lanes 2 and 9), 4 (lanes 3 and 10), 8 (lanes 4 and
11), 12 (lanes 5 and 12), 24 (lanes 6 and 13) and 24a in the presence of AraC (lanes 7 and 14) h p.i. The membranes were first probed with anti-Serp-1
antibody, stripped and probed for M-T7 and actin (loading control).
doi:10.1371/journal.ppat.1003465.g004
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Figure 5. M029 is expressed as an early/late viral protein, associated with virions and is localized in the nucleus and cytoplasm of
virus-infected cells. A) Construction of vMyx-M029V5N. A plasmid having N-terminal V5 sequence –tagged M029 was constructed by PCR. The final
recombination plasmid has 59 partial M028L sequence, V5-tagged M029 sequence and M030L sequence and was constructed by three-element
M029 Inhibits PKR and Conscripts RHA/DHX9
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and cytoplasmic compartments of the infected cells, with some
cells having relatively higher levels of M029 in the nucleus (Fig. 5E,
Panels 1 and 2). We also infected RK13 cells with the same virus at
an MOI of 0.1 for 24 hrs. At this time point, virus-infected cells
express GFP driven by a viral early/late promoter, however there
were no significant changes in the nuclear and cytoplasmic
localization of V5-tagged M029 in the infected cells at the late
time points (Fig. 5E, panels 3 and 4). Infection with vMyx-GFP
served as a control (Fig. 5E, column 1).
M029 interacts with PKR in a dsRNA-dependent fashion
and binds an additional host protein DHX9/RHA by direct
protein-protein interactions
We next investigated whether M029 protein interacted with any
specific host protein(s) in virus-infected cells that might regulate
MYXV replication in diverse cell types, given that in the absence
of functional M029 expression, MYXV became nonpermissive in
so many diverse mammalian cell types. For this proteomic study,
we primarily focused on virus-infected human cells in order to
identify any potential M029 interacting cellular proteins that
potentially regulate MYXV tropism. Human A549 cells were
infected with vMyx-GFP or vMyx-M029V5N viruses, the protein
complexes bearing V5-tagged protein were isolated using anti-V5
antibody by co-IP and unique protein bands present in vMyx-
M029V5N samples were identified by mass spectrometry. In order
to identify all the potential M029 interacting proteins, proteomic
analysis was performed with samples that were not treated with
RNase V1, a ribonuclease that cleaves double-stranded RNAs.
Multiple distinct co-precipitating proteins were identified from the
vMyx-M029V5N infected sample (Table 1). However, when the
same samples were treated with RNase V1, many of the protein
bands were disappeared (data not shown). One of the identified
proteins was RNA Helicase A (RHA), also known as DHX9,
which was consistently present in the immunoprecipitates with V5-
tagged M029. This interaction of M029 with DHX9 was
confirmed from multiple human virus-infected cells, including
HeLa, A549 and THP1 cell lines (Fig. 6A lane 2 and data not
shown). The presence of PKR was also detected in the same anti-
V5 co-IP samples by Western blot using anti-PKR antibody
(Fig. 6A, lane 6). The interactions between V5-tagged M029 and
DHX9 or PKR were also confirmed by co-IP using anti-DHX9 or
anti-PKR antibody, respectively and detection of tagged M029
using anti-V5 antibody (Fig. 6A lanes 10 and 12). Next we tested
whether interaction of M029 with PKR or DHX9 might be
dependent on linkage via dsRNA, since both the host proteins and
M029 all possess dsRNA-binding domains. Treatment with
ssRNase, RNaseA/T1, did not affect the interactions of M029
with either DHX9 or PKR (Fig. 6A lanes 4 and 8). In contrast,
when the lysates were pre-treated with RNase V1, which cleaves
dsRNA substrates, the amount of PKR that interacted with M029
using dsRNA was no longer observed. However, DHX9 was still
detected in the samples precipitated with anti-V5 after being
treated with RNase V1 (Fig. 6B compare lanes 2 and 4). These
results suggest that M029 protein interacts with PKR in a dsRNA-
dependant manner but interacted with DHX9 independently of
dsRNA. We also confirmed protein-protein interactions between
M029 and DHX9 in the absence of PKR, using the cell lysates
prepared from PKR stable knockdown HeLa cells (Fig. 6C).
recombination of the Multisite Gateway system. The virus also has a eGFP expression cassette inserted at the intergenic region between M135-M136
locus; B) M029 protein is expressed as an early/late gene product in infected rabbit cells. RK13 cells were left uninfected (M) (lanes 1) or were infected
with vMyx-M029V5N at an MOI of 3. Cells were collected at1, 2, 4, 6, 9, 12, and 24 (lanes 2 to 8) and 24a in the presence of AraC (lane 9) h p.i. The
membranes were first probed with anti-Serp-1 antibody, stripped and probed for M-T7 and actin (loading control). C) M029 is packaged into MYXV
virions. Gradient purified vMyx-GFP (lane 1) and vMyx-M029V5N (lane 2) viruses were separated on 12% SDS-PAGE gels for Western blotting. V5-
tagged M029 was detected using an anti-V5 antibody. D) M029 is located in the membrane and core of the MYXV virion. Gradient purified vMyxGFP
(lanes 1 and 2), vMyx-M029V5N (lanes 3 and 4) and vMyx-M029ID (lanes 5 and 6) were treated with detergent and DTT to separate the membrane (M)
and core components (C) of the virions. The fractions were separated on SDS-PAGE for Western blotting, followed by detection using an anti-V5
antibody, stripped and probed with anti-M071 antibody as control to detect successful separation of membrane and core fractions. E) M029 localizes
to the nuclear and cytoplasmic compartments of the infected cells. RK13 cells grown on glass coverslips were infected with the indicated viruses at a
MOI of 5.0 or 0.1. After 3 or 24 hr after infection, cells were fixed, permeabilized, and incubated with anti-V5 monoclonal antibody, followed by Texas
Red-conjugated goat anti-mouse antibody. DNA in nuclei and viral factory was stained with DAPI (shown in blue). Cells were imaged using a Leica
laser scanning confocal microscope. The localization of V5-tagged M029 is shown in red and the expression of GFP is shown in green.
doi:10.1371/journal.ppat.1003465.g005
Table 1. Cellular proteins associated with V5-tagged M029 immunoprecipitations.
Protein name Mass (Da)
ATP-dependent RNA helicase/DHX9 142,140
Long isoform of splicing factor, proline and glutamine rich 76,149
dsRNA-binding protein staufen homolog 2 59,000
Heterogeneous nuclear ribonucleoproteins A/B 35,967
KH domain containing RNA binding signal transduction-associated protein 1 48,228
Isoform A1-B of heterogeneous nuclear ribonucleoproteins A1 38,747
Heterogeneous nuclear ribonucleoproteins A2/B1 37,430
ADP/ATP translocase 2 32,853
60S ribosomal protein L7 29,227
Single stranded DNA binding protein 17,259
60S ribosomal protein L30 12,784
doi:10.1371/journal.ppat.1003465.t001
M029 Inhibits PKR and Conscripts RHA/DHX9
PLOS Pathogens | www.plospathogens.org 8 July 2013 | Volume 9 | Issue 7 | e1003465
PKR is activated in cells infected with M029-minus MYXV
leading to an abortive infection
We have examined the role of PKR activation in the regulation
of MYXV infection in the absence of functional M029 protein.
Infection of human cells with vMyx-M029ID or vMyx-M029KO
viruses activated PKR signaling soon after infection, as compared
to control wildtype-MYXV infection. In the M029-minus virus-
infected cells, high level of phospho-PKR was detected 8 hpi
(Fig. 7A, compare lanes 4 to 6 with lanes 11 to 13) and could be
observed even at 4 hpi (Fig. 7B, lanes 4 to 8). No phospho-PKR
was detected before 12 hpi in the samples infected with control
vMyx-GFP, suggesting that repression of PKR activation by M029
is key for permissive MYXV replication. Importantly, we noticed
that treatment of virus-infected cells with AraC prevented the
phosphorylation of PKR induced by both M029-minus viruses.
This suggests that the dsRNA ligands, which are preferentially
synthesized in poxvirus-infected cells following DNA replication,
are necessary for PKR phosphorylation and are sequestered by
M029 (Fig. 7A and B).
PKR knockdown in human cells rescues M029-minus
virus replication in human cells
Identification of PKR as an M029 interacting host protein, and
the activation of PKR in virus-infected cells in the absence of
M029 expression, both suggest that PKR can play significant
role(s) in the innate anti-viral response initiated in PKR-competent
mammalian cells in response to MYXV infection. To study the
direct role of PKR in MYXV infection, we first knocked down
PKR expression in various human cells by transient transfection of
an siRNA pool targeting human PKR. Knocking down PKR
expression caused significant increase in the replication of both
vMyx-M029KO and vMyx-M029ID viruses in all tested human
Figure 6. M029 interacts with human PKR and DHX9/RHA in virus-infected cells. A) HeLa cells were infected with vMyx-GFP (lanes 1, 3, 5, 7,
9 and 11) or vMyx-M029V5N (lanes 2, 4, 6, 8, 10 and 12) for 24 h. Cell lysates were untreated or treated with RNAse A/T1(50 mg/ml RNase A and 125 u/
ml RNase T1) at 4uC and co-IP was performed using mouse anti-V5 antibody (lanes 1 to 8), rabbit anti-PKR (lanes 9 and 10) or rabbit anti-DHX9.
Proteins associated with the complex were separated on 12% SDS-PAGE, transferred to a PVDF membrane and immunoblotted. The bots were
probed with rabbit anti-DHX9 (lanes 1 to 4), rabbit anti-PKR (lanes 5 to 8) or mouse anti-V5 (lanes 9 to 12). B) M029 interaction with PKR is mediated
by dsRNA but interaction with DHX9 is dsRNA independent. HeLa cell were infected with vMyxM029V5N for 24 h, cell lysates were treated with RNase
V1 (10 u/ml) at 4uC over-night and co-IP was performed using mouse anti-V5 (lanes 1 and 2) or rabbit anti-DHX9 (lanes 3 and 4). After transfer the
blots were probed with different antibodies. C) M029 interaction with DHX9 is independent of PKR. HeLa cell lines with constitutive knock down of
PKR (HeLa shPKR, described in figure 9) were infected with vMyx-M029V5N for 24 h, cell lysates were treated with RNase V1 at 4uC overnight and co-
IP was performed using mouse anti-V5 (lanes 1 and 2) or rabbit anti-DHX9 (lanes 3 and 4). After transfer the blots were probed with different
antibodies.
doi:10.1371/journal.ppat.1003465.g006
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cell lines such as A549, HeLa, THP1, and primary human
fibroblast cells GM02504 (Fig. 8A, and not shown). In order to
further analyze the role of PKR and achieve more consistent gene
expression knockdown, a lentivirus containing shRNAs targeting
PKR was used to construct human cell lines with constitutively
reduced PKR protein levels. In PKR-knockdown HeLa cells
(HeLa shPKR), the replication of wildtype MYXV, vMyx-GFP
was unchanged (Fig. 9 A and B). In these PKR knockdown HeLa
cells, the replication of both vMyx-M029KO and vMyx-M029ID
viruses increased about two logs, as monitored by single step
growth curves (Fig. 9B). The replication of M029-defective viruses
in HeLa shPKR cells also correlated with the formation of viral
foci when infected with low MOI (Figure 9C, column 2) and also
restored synthesis of late viral protein in the infected cells (Fig. 9D
compare lanes 12 and 13 with lanes 5 and 6).
MYXV sensitivity to type I IFN is enhanced in the absence
of functional M029
The members of E3 family of proteins are believed to be key
players in mediating resistance against IFN [25]. Using M029-
minus mutants of MYXV, we have tested whether M029 plays a
functional role in resistant to type I IFN in human A549 cells,
which respond robustly to type I IFN [40]. We constructed stable
PKR knockdown A549 cells using lentiviruses containing shRNAs
targeting PKR. In the A549 or ShControl A549 cells, treatment
with IFNb resulted in the formation of smaller foci by vMyx-GFP
and slowed the replication kinetics of M029-expressing MYXV
(Fig. 10A and not shown). However, significant differences
(P,0.01) were observed in the PKR knockdown A549 cells. In
these shPKR-A549 cells, the rescued replication of M029-defective
virus, vMyx-M029ID, was almost abolished in the presence of
IFNb (Fig. 10A bottom panels). When progeny virus was titered,
we also observed significant reduction in the vMyx-M029ID virus
production in the PKR-knockdown cells that had been interferon-
treated (Fig. 10B, 72 hpi).
DHX9/RHA is required for replication of MYXV in human
monocytic cells
In order to investigate the role of RHA/DHX9 in MYXV
replication in human cells, we used siRNA to knockdown the
expression of DHX9 in various human cells. Knocking down
RHA/DHX9 protein expression in HeLa, A549 or THP1 cells did
not rescue the M029 defective virus infection, nor were any
significant changes in the replication of wildtype-MYXV detected
(Fig. 11A and not shown). Since DHX9/RHA has also been
reported to interact with PKR ([41] and our results), we then
decided to investigate whether it has any role associated with PKR
functions. We therefore transiently knocked down the expression
of RHA/DHX9 in the PKR stable knockdown shPKR human cell
lines. In the shPKR-THP1 cell lines, where M029 defective virus
Figure 7. M029 blocks early activation of PKR signaling in MYXV-infected cells. A) HeLa cells were left uninfected (M) (lanes 1 and 8) or
infected with vMyx-GFP (lanes 2 to 7) or vMyx-M029ID (lanes 9 to 14) at an MOI of 3. Cells were collected at 2 (lanes 2 and 9), 4 (lanes 3 and 10), 8
(lanes 4 and 11), 12 (lanes 5 and 12), 24 (lanes 6 and 13) and 24a in the presence of AraC (lanes 7 and 14) h p.i. The membranes were first probed with
anti phospho PKR (pPKR) antibody, stripped and probed for PKR and actin (loading control). B) Western blots showing expression of pPKR, PKR and
actin in vMyx-M029ID infected samples collected after 2, 3, 4, 6, 8, 12, 24 hrs and 24a in the presence of AraC from HeLa cells. The relative level of
phosphorylated PKR is indicated.
doi:10.1371/journal.ppat.1003465.g007
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replication has been rescued, we observed significant decrease
(P,0.05) in the replication of vMyx-M029ID compare to vMyx-
GFP, when RHA/DHX9 was knocked down (Fig. 11B). This was
reflected by a decrease in the progeny virus titer when monitored
during a one-step virus replication cycle (Fig. 11C). Knocking
down RHA/DHX9 in the stable shPKR-THP1 cells also reduced
the synthesis of both early (M-T7) and late (Serp-1) viral proteins
in the vMyx-M029ID infected cells (Fig. 11D). However, the
synthesis of both viral early and late mRNAs remained unaffected
in these cells, suggesting that RHA/DHX9 may have role in viral
protein synthesis (Figure S4). Thus, in stark contrast to PKR,
whose activation was inhibitory to MYXV in all the human cells
tested, RHA/DHX9 is required for optimal MYXV replication in
human THP-1 myeloid cells when PKR was depleted or absent.
M029 is essential for pathogenesis of MYXV in
susceptible European rabbits
We next examined the role of M029 in the pathogenesis of
MYXV in the European rabbits, where MYXV causes lethal
disease myxomatosis. Viruses (1000 FFU) were delivered by
intradermal route of inoculation to the flanks of susceptible
European rabbits. In this study, we used mock infected (PBS),
wild-type parental MYXV Lausanne strain (vMyx-Lau), or
revertant viruses containing a rescued intact M029 gene as
controls. Infection with M029-revertant viruses showed similar
progression of myxomatosis and same mortality rates (100%) as
that caused by the parental wild-type virus (Table 2 and Fig. 12).
The vMyx-M029KO and vMyx-M029ID viruses induced either
no, or very mild, primary lesions at the primary inoculation site,
and no observable disease indications were detected at all
throughout the entire course of observation. All the animals
infected with these M029-mutant viruses survived the initial
infection with no noticeable symptoms (Table 2). These observa-
tions suggest an essential role for M029 in the infections and
pathogenesis of MYXV in the susceptible European rabbit hosts.
We also tested whether abortive infection of M029 mutant viruses
might function as potential vaccines for myxomatosis, as caused by
the wild-type vMyx-Lau infection. However, we observed low but
variable protection results, suggesting that the M029-mutant
infections aborted so quickly at the primary site of inoculation that
very little in the way of acquired immune responses were
generated.
Discussion
We have demonstrated that M029 is both a critical host range
factor for MYXV replication in a wide spectrum of diverse
mammalian cell types as well as a critical virulence factor for
myxomatosis in the European rabbits. Our inability to isolate pure
recombinant M029-defective MYXV constructs using any of the
standard mammalian cell lines where the parental MYXV can
robustly replicate indicated that M029 plays essential function(s) in
MYXV replication for most mammalian cells. The M029-minus
viruses were only successfully isolated away from complementing
parental MYXV and propagated as pure clones in cell lines that
stably express VACV E3, a complementing comparable poxvirus
protein. The purified vMyx-M029KO and vMyx-M029ID viruses
that were grown in these E3-complementing RK13 cells exhibited
severe defects in replication in essentially all established mamma-
lian cell lines originated from diverse species, where the parental
wildtype-MYXV replicates permissively. The most profound
tropism defect of the M029-mutant viruses was their complete
inability to replicate in any of the tested cells derived from humans
(eg HeLa, A549, THP-1, various cancer cell lines, primary
fibroblasts, etc), non-human primates (eg BSC40) and mouse (eg
NIH3T3) (Fig. 3 and 4). In these cell lines, no expression of viral
late proteins was detected in the absence of M029 expression. On
the other hand, abundant expression of early viral proteins was
Figure 8. Transient knocking down of PKR by siRNA can rescue the replication of vMyx-M029KO and vMyx-M029ID. A) HeLa and
A549 cells were transiently transfected with control siRNA (panels in rows 1 and 3) or siRNAs targeting human PKR (final concentration of 100 nM)
(panels in rows 2 and 4) for 48 h before infection with vMyx-GFP (column 1), vMyx-M029KO (column 2) and vMyx-M029ID (column 3) at an MOI of 3
for 48 h. B) Western blot of siRNA transfected cell lysates showing the level of PKR knock down in HeLa (Lane 2, panel 1) and A549 cells (lane 4, panel
3).
doi:10.1371/journal.ppat.1003465.g008
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detected from M029-minus viruses at a comparable level with
wildtype-MYXV infection (Fig. 3B), suggesting that there was no
defect in virus binding, entry, or early viral gene expression. Both
vMyx-M029KO and vMyx-M029ID viruses were also unable to
replicate in rabbit RL5 T lymphocytes, and although they were
capable of at least some detectable progeny virus synthesis in
RK13 cells, replication kinetics were reduced and cell-cell
transmission was compromised. Slower replication kinetics of
M029-defective viruses was also observed in hamster BHK21 cell
lines. In both RK13 and BHK21 cells, the synthesis of viral late
protein was significantly delayed, which resulted in a reduced
progeny virus production at 12 hpi when tested by single step
growth curve analysis. It is possible that the level of dsRNA
produced by the viruses in these semi-permissive cell lines is lower
than the completely nonpermissive cell lines, as has been suggested
for VACV [16].
The deletion or insertional disruption of M029 also resulted in
the elimination of essentially all disease symptoms associated with
myxomatosis in susceptible rabbits. This extreme attenuation was
associated with the absence of obvious viral spread and extreme
Figure 9. Stable knock down of PKR can rescue the replication of M029-defective MYXV in human cells. HeLa cell lines with constitutive
knockdown of PKR (shPKR) were constructed by infecting parental HeLa with a lentivirus packaged with shRNAs targeting PKR mRNA. A control HeLa
cell line (shControl) was also constructed by infecting HeLa cells with a lentivirus packaged with control shRNAs. Single step growth curves of MYXV
infection in A) shControl B) shPKR cells. The indicated cells were infected with vMyx-GFP, vMyx-M029KO or vMyx-M029ID at an MOI of 5, and then
cells were collected at 0, 6, 24, and 48 h p.i. The virus titers were determined in triplicate following serial dilution onto RK13-E3 cells. Data are
representative of three independent experiments. C) Fluorescence microscope images of infected shControl (columns 1 and 3), and shPKR (columns 2
and 4) cells. The images were taken using an inverted fluorescence microscope using a lens with 610 magnification at 48 h p.i. The cells were
infected with a low MOI of 0.5 (columns 1 and 2) and high MOI of 3.0 (columns 3 and 4) with vMyx-GFP (top panels), vMyx-M029ID (middle panels)
and vMyx-M029KO (bottom panels). D) Expression of viral early (M-T7) and late (Serp-1) proteins in the infected shControl and shPKR cell lines. Cells
were left uninfected (M) (lanes 1 and 8) or were infected with vMyx-GFP (top panels) or vMyx-M029ID (middle panels) at an MOI of 3. Cells were
collected at 2, 4, 8, 12, 24 and 24a in the presence of AraC (lanes 7 and 14) h p.i. The membranes were first probed with anti-Serp-1 antibody, stripped
and probed for actin (loading control).
doi:10.1371/journal.ppat.1003465.g009
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reductions in the replication of virus at the primary site of
infection. Following full recovery of the M029-mutant infected
animals, very variable levels of protection was generated against
subsequent challenge by wildtype MYXV, suggesting that virus
replication at the primary inoculation site was likely aborted
quickly before the elements of acquired immune responses were
significantly engaged.
Analyzing the distribution of V5-tagged MYXV M029 protein
revealed that M029 was expressed at an early time points of
infection and was packaged into infectious virions (Fig. 5), which
suggests a critical role of M029 in the modulation of host innate
sensing/signaling pathways during early stages of infection. This
observation is particularly important because VACV E3 has not
been reported in virions and we were also unable to detect E3 in
purified VACV particles using comparable strategy used for
vMyx-M029V5N ([39], and data not shown). Localization studies
using immunofluorescence microscopy indicated that M029
protein is localized to both the nuclear and cytosolic compart-
ments of MYXV-infected cells. This same cellular localization of
M029 was also observed when V5-tagged M029 was transiently
expressed in uninfected cells using plasmids under CMV promoter
(data not shown), suggesting that nuclear-cytoplasmic dual
localization is not dependent on viral infection. Like M029,
VACV E3 protein is also localized in both the nucleus and
cytoplasm, however, the nuclear localization of E3 is dependent on
the N-terminal 83 amino acid residues, which are missing in the
M029 protein [26,42]. This suggests that M029 may have
acquired a different mechanism for nuclear localization.
The major role of VACV E3 is thought to antagonize the PKR-
mediated anti-viral functions of the infected host cell, which are
upregulated by IFN and activated by dsRNA [4]. eIF2a is a
primary cellular substrate that becomes phosphorylated in cells
infected with E3-minus VACV, which then leads to the global
inhibition of host and viral protein synthesis, the induction of
apoptosis and eventual inhibition of virus replication. Infection
with VACVDE3 resulted in the phosphorylation of both PKR and
eIF2a, however the defect of VACVDE3 can be rescued in PKR-
deficient HeLa cells [43]. In the PKR-deficient cells, late viral
protein synthesis was restored and virus-induced apoptosis was
also abolished, which resulted in productive virus replication even
in the absence of E3 expression. PKR is one of the host innate
immune proteins that undergo rapid evolution in order to escape
being targeted by viruses capable of anti-PKR strategies, such as
poxviruses [44].
Figure 10. Absence of M029 enhances MYXV sensitivity to Type I IFN. Human A549 cell lines with constitutive knockdown of PKR
(shPKRA549) or a control (shControl A549) were constructed as described for HeLa. The cells were infected with vMyx-GFP (top panel) or vMyx-
M029ID with or without treatment of human IFNb (1000 U/ml). A) Fluorescence images were taken after 48 h p.i. with an MOI of 0.1. B) Virus was
tittered after 1 and 72 h of p. i. using RK13-E3 cells. C) A549 cells were infected with VSV with an MOI of 0.1 with or without treatment of human IFNb
(1000 U/ml). Virus was tittered after 24 h p.i. using A549 cells to determine the titer. Data are mean 6 SD of triplicate samples from one experiment
and are representative of two independent experiments. **P,0.01 compared with vMyx-M029ID infection.
doi:10.1371/journal.ppat.1003465.g010
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Figure 11. RHA/DHX9 is required for the rescue of M029-defective MYXV replication in human cells. A) Transient knockdown of
endogenous RHA/DHX9 alone did not induce rescue of M029 mutants in THP1 cells. THP1 cells were transiently transfected with PKR siRNA (left
column), DHX9 siRNA (middle column) or control siRNA (right column) for 48 h before infection with vMyx-GFP (top panels) or vMyx-M029ID (bottom
panels) at an MOI of 3 for 48 h. The images were taken using an inverted fluorescence microscope. B) Transient knock down of DHX9 in shPKR THP1
cell lines prevent the rescue of M029 defective viruses. THP1 cell lines with constitutive knockdown of PKR (shPKR-THP1) were constructed by
infecting parental THP1 with a lentivirus packaged with shRNAs targeting PKR mRNA. ShControl and ShPKR-THP1 cells were transiently transfected
with DHX9 siRNA or control siRNA for 48 h before infection with vMyx-GFP or vMyx-M029ID at an MOI of 3. Fluorescent microscope images of vMyx-
GFP (top panels) or vMyx-M029ID (bottom panels) after 48 h p.i. C) vMyx-GFP or vMyx-M029ID infected cells were collected at 2, 24 and 48 h p.i. for
titration of virus production using RK13-E3 cells. Data are mean 6 SD of triplicate samples from one experiment and are representative of two
independent experiments. ** P,0.01 compared with un-transfected samples. D) vMyx-GFP (lanes 1 to 6) or vMyx-M029ID (lanes 7 to 12) infected
shPKR THP1 cells after DHX9 or control siRNA transfection were harvested at 2, 4 and 24 h p.i and proteins were detected for Serp-1, M-T7, DHX9 and
actin (as loading control). The relative level of SERP-1, M-T7 and DHX9 protein expression is indicated.
doi:10.1371/journal.ppat.1003465.g011
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Based on the profound host range phenotype of M029-defective
viruses in a wide spectrum of mammalian cells, we created MYXV
that expressed V5-tagged M029 and performed co-IP and mass-
spectrometry to identify putative host binding partner proteins that
might be functionally targeted by M029. Based on the previous
report that PKR interacts with VACV E3, we first identified
cellular PKR as an M029 interacting protein in various human
cells. The interaction of PKR and M029 was validated by co-IP
assay in virus-infected mammalian cells with either V5 or PKR
antibody (Figure 6A). Significantly, this PKR-M029 protein
interaction was eliminated by digestion with RNaseV1, which
cleaves dsRNA, but not with RNaseA/T1 that targets only
ssRNA, suggesting that this interaction requires dsRNA. Since
both PKR and M029 possess dsRNA-binding domains, it is
presumed that these proteins become linked via dsRNA bridging.
VACV E3, on the other hand, has been reported to have direct
protein-protein interaction with PKR; however, the samples were
not treated with an RNase that specifically cleaves dsRNA [45,46].
Although M029 interacts with PKR indirectly via dsRNA, this
interaction is still biologically relevant, since the replication of
M029-minus MYXV viruses were specifically rescued in PKR
knockdown cells. In stable PKR knockdown human cells, the
synthesis of viral late proteins was fully restored and allowed
complete replication and progeny virus formation by vMyx-
Table 2. Pathogenesis of vMyx-M029KO and vMyx-M029ID in New Zealand White (NZW) rabbits.
Day vMyx-Lau/vMyx-M029KO-Rev/vMyx-M029ID-Rev vMyx-M029KO vMyx-M029ID
0 For each of the indicated viruses two female
NZW rabbits were inoculated intradermally with
103 FFU/0.1 ml.
Four female NZW rabbits were inoculated
intradermally with 103 FFU/0.1 ml.
Three female NZW rabbits were inoculated
intradermally with 103 FFU/0.1 ml.
4 All the rabbits had red and swollen primary
lesion with an average diameter of 2.5 cm
No sign of primary lesion in all four
rabbits
One rabbit had redness at the inoculation site
5 All the rabbits developed secondary lesions on
eyes and ears; satellite lesions detected surrounding
the primary lesion
No sign of primary lesion in all four
rabbits
Primary lesion became red and mild swollen in
one rabbit
6 Primary lesion red, swollen, and necrotic; numerous
secondary lesions were detected on eyes, ears and
nose in all the rabbits
No sign of primary lesion in all four
rabbits
Another rabbit had redness at inoculation site
7 Primary lesion increased in diameter to 3.5 cm;
eyes, ears, nose, mouth are swollen in all the
inoculated rabbits
No sign of primary lesion in all four
rabbits
All three rabbits had red and mild swollen primary
lesion
8–9 All the rabbits had primary lesions which were
4.5 to 5.5 cm; severe signs of myxomatosis; rabbits
were sacrificed due to severity of the symptoms
Two rabbits had red and mild swollen
area where virus inoculated
Primary lesion red and swollen, diameter 1 cm;
few secondary lesions detected on ears and nose
in all three rabbits
11–12 Only one rabbit had small red,
swollen area
All three rabbits had primary lesions which were
red, swollen, necrotic; no secondary lesions
19–20 Rabbits were re-challenged with
vMyx-Lau with 103 FFU/0.1 ml. Three
out of four rabbits were protected from
myxomatosis after re-challenge.
Rabbits were re-challenged with vMyxLau with
103 FFU/0.1 ml. No sign of myxomatosis detected
in the re-challenged rabbits.
doi:10.1371/journal.ppat.1003465.t002
Figure 12. M029 is essential for MYXV pathogenesis in European rabbits. Both vMyx-M029KO and vMyx-M029ID viruses can no longer
cause myxomatosis in European rabbits. The overall physical condition and disease progression were evaluated daily using a clinical score system,
and the average daily score for the rabbits representing a particular treatment group was calculated and plotted.
doi:10.1371/journal.ppat.1003465.g012
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M029KO and vMyx-M029ID (Fig. 9), which demonstrates that
PKR is a major functional target for M029 host range functions, as
it is for VACV E3.
In addition to PKR, we also identified several other cellular
RNA binding proteins that were consistently present in the co-IP
samples for V5-tagged M029 in virus-infected human cells.
Among these, we were particularly interested in investigating the
potential interaction of M029 with RHA, a cellular RNA
helicase, also known as DHX9. RHA/DHX9 is a 130 kDa
protein that belongs to the DEXD/H box family of proteins,
which can unwind both double-stranded RNA and DNA, and
can also regulate cellular processes such as pre-mRNA splicing,
ribosome biogenesis, transcription, RNA nuclear export, and
translation initiation [47,48,49]. RHA/DHX9 is also associated
with regulating the replication efficiencies of various RNA
viruses, including HIV-1, HCV, FMDV and influenza A
[50,51,52,53]. These viral regulatory functions of RHA/DHX9
are mediated by interactions with unique viral proteins, for
example, the Gag protein of HIV and NS1 protein of Influenza
A virus [53,54]. DHX9 also function as a dsRNA sensor in
selected cell types [55]. In one recent report, it was demonstrated
that NS1 can rescue VACVDE3 virus replication, at least in vitro
[24], and thus we postulated that RHA/DHX9 might also have
potential role(s) in some aspect of poxvirus tropism. VACV E3
has also been reported to interact with a wide spectrum of host
proteins, including RHA/DHX9, but the functional significance
of this particular protein interaction has not been reported [56].
The interaction of DHX9/RHA with V5-tagged M029 protein
was validated in virus-infected cells by co-IP assay using either
anti-RHA/DHX9 or V5 antibody. Interestingly, unlike the
PKR-M029 interaction, the RHA-M029 protein interaction was
not eliminated by digestion of dsRNA with RNaseV1 (Fig. 6A
and B), suggesting that interaction between RHA/DHX9 and
M029 is through direct protein-protein interactions. RHA/
DHX9 has also been reported to interact with PKR, and is in
fact a substrate of activated PKR kinase [41]. In the virus
infected cells we have not observed any alteration in the nuclear
localization of DHX9 (data not shown). We therefore assessed
the potential biological significance of RHA/DHX9 interaction
with M029, and discovered that this interaction regulated virus
host range in a very cell-specific fashion. Knockdown of RHA/
DHX9 gene expression in human THP-1 myeloid cells that had
been depleted of PKR reduced the replication and viral protein
synthesis for both the M029-expressing vMyx-GFP and signif-
icantly for the M029-defective viruses, indicating that RHA/
DHX9 can play a required pro-viral regulatory role in the virus
life cycle of MYXV in monocytic cell lines when PKR is absent
or repressed.
It is well known that certain individual virus-encoded
immunomodulators can inhibit multiple ligands or pathways.
For example, the M-T7 protein of MYXV binds and inhibits
both rabbit interferon-gamma and diverse chemokines, the
SECRET family of orthopoxvirus proteins can bind and co-
inhibit both TNF and chemokines, the M-T5 intracellular host
range factor of MYXV targets both Akt and the Skp1 component
of the cellular SCF complex, and the M13 protein of MYXV
targets both ASC-1 of the inflammasome complex and NF-kB1
[57,58,59,60]. However, this is the first report of a single viral
host range protein, M029, with two different functional cellular
targets, one of which (PKR) is bound and inhibited to alleviate
anti-viral signaling, while the other (RHA/DHX9) is bound and
conscripted as a pro-viral effector to upregulate viral replication
in a cell-specific fashion.
Materials and Methods
Ethics statement
All animal studies were performed following the IACUC
protocol number IACUC #201005008 and titled ‘‘Studies in
Poxvirus Host Range Genes and Tropism’’. This protocol was
approved by the University of Florida Animal Care Services in
accordance with the guidelines set by the Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC).
Reagents and antibodies
Rabbit polyclonal antibody for PKR was purchased from Cell
Signaling Technology. Rabbit polyclonal antibody for DHX9,
mouse monoclonal antibody for DHX9 and PKR from Santa
Cruz Biotechnology, rabbit polyclonal antibody for phospho PKR
from Millipore, mouse monoclonal antibody for b-actin was
obtained from Ambion and mouse antibody for V5 from
Invitrogen. HRP-conjugated goat anti-rabbit and anti-mouse
IgG antibodies were purchased from Jackson ImmunoResearch
Laboratories. Generation of rabbit polyclonal and mouse mono-
clonal antibodies against MYXV proteins M-T7 and Serp1 was
described before [61,62].
Cell lines and cell culture
Rabbit cell line RK13 (ATCC# CCL-37), human cell lines
HeLa (ATCC# CCL-2), and A549 (ATCC# CCL-185), primary
human fibroblasts GM02504 [40], monkey cell line BSC-40
(ATCC# CRL-2761), hamster kidney cell lines BHK21 (ATCC#
CCL-10), mouse embryonic fibroblast cell lines NIH3T3
(ATCC# CRL-1658) all were cultured in Dulbecco minimum
essential medium (DMEM; Invitrogen) supplemented with 10%
fetal bovine serum (FBS; Gibco), 2 mM glutamine (Invitrogen) and
100 mg of penicillin-streptomycin (pen/strep; Invitrogen)/ml.
Human monocytic THP1 (ATCC# TIB-202) and rabbit CD4+
T cells RL5 (Liu et al., 2011) were cultured in RPMI 1640
medium (Lonza, BioWhittaker) supplemented with 10% FBS, and
100 mg of pen/Sterp per ml. All cultures were maintained at 37uC
in a humidified 5% CO2 incubator.
RK13 cells expressing VACV E3 protein (RK13-E3) was
generated by transfecting RK13 cells with pcDNA3.1 (Geneticin
resistance)-VACV E3L plasmid. Stably transfected cells were
selected by the presence of 500 mg/ml Geneticin. Several clones
were isolated and analyzed for expression of E3. The clone which
showed highest level of E3 expression was used for virus
propagation. RK13 cells expressing VACV E3 and K3 proteins
(RK13-E3K3) was generated by transfecting RK13-E3 cells with
pcDNA3.1 (Zeocin resistance)-VACV K3L-26Flag tag plamid.
Stably transfected cells were selected by the presence of 300 mg/ml
Zeocin and 500 mg/ml Geneticin and maintained for 20 days
under selection. The RK13-E3K3 cells were polyclonal.
Construction of recombinant viruses
To make M029 mutant viruses, recombinant plasmids were first
constructed using MultiSite Gateway Pro (Invitrogen) system. In
one of the construct, vMyx-M029ID, an eGFP expression cassette
(driven by a poxvirus synthetic early/late promoter [27]) was
inserted into the M029 ORF. In another construct, vMyx-
M029KO, the entire M029 gene was replaced by the eGFP
expression cassette. For both the constructs upstream and
downstream hybridizing sequences were amplified by PCR using
specific primers to create entry clones by Gateway BP recombi-
nation system with appropriate pDONR vectors. The final
recombination plasmids were constructed by recombination of
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three entry clones with a destination vector (pDEST40; Invitrogen)
and using Gateway LR recombination system. The vMyx-
M029ID and vMyx-M029KO viruses were constructed by
infecting RK13-E3 and RK13-E3K3 cell lines respectively with
wild-type MYXV Lausanne strain (vMyx-Lau), followed by
transfection of the recombination plasmids. Multiple rounds of
foci purifications were performed on the same cell lines based on
eGFP expression and continued until pure foci of M029 mutant
viruses were isolated. Virus was amplified from pure isolated foci
and recombination was confirmed by PCR using appropriate
primers (Figure 1). The recombinant virus, vMyx-M029V5N,
where a N-terminal V5 tag was inserted in front of the M029 ORF
was constructed using similar method. The virus also contains an
eGFP expression cassette driven by a poxvirus synthetic early/late
promoter in the M135-136 locus [28]. The revertant myxoma
viruses for M029 mutants, vMyx-M029ID-Rev and vMyx-
M029KO-Rev were constructed by infecting nonpermissive (for
M029 mutants) BSC40 cells with M029 mutants, followed by
transfection with a revertant plasmid containing the myxoma virus
M028, M029 and M030 gene sequences. The viruses were
purified by multiple rounds of focus purification based on
nonfluorescent foci formation, which was confirmed by PCR
using the appropriate primers. In these revertant viruses an eGFP
cassette was also inserted in the M135-136 locus.
Single-step growth curve
Cells were seeded into twelve-well dishes and semi-confluent
monolayers (16105 cells) were infected with different myxoma
viruses at an MOI of 5 for one hour. The virus containing media
was removed, and the cell monolayer was washed with complete
medium and incubated with fresh complete medium. Samples
were collected at various times post-infection and stored in 280uC
until processed. The samples were freeze-thawed at 280uC and
37uC for three times and sonicated for one minute to release the
viruses from infected cells. The virus was titrated back onto RK13-
E3L monolayers by serial dilution in triplicate. After 48 hrs of
infection the numbers of fluorescent foci were counted from each
dilution and calculated the virus titer.
Viral preparation
Construction of a wild-type MYXV that express GFP under the
control of a synthetic VACV early-late promoter was described
previously [28]. The vMyx-M029KO and vMyx-M029ID viruses
were grown and amplified in RK13-E3 cells. All other myxoma
viruses were grown in BSC40 cells. Viruses were purified by
centrifugation through a sucrose cushion and two successive
sucrose gradient sedimentations as described previously [60].
Vesicular stomatitis virus (VSV) expressing GFP was prepared as
described before [63].
Western blot analysis
The mock or infected cells were harvested at different time
points after infection with viruses, washed with PBS and stored at
280uC or processed immediately with RIPA lysis buffer
(50 mMTris, 150 mMNaCl, 0.1% SDS, 0.5% sodium deoxycho-
late, 1% NP40, 1 mM PMSF, and protease inhibitor cocktail
(Roche). Amount of total proteins were estimated by Bradford
assay (Bio-Rad) and equal amount of total proteins were used for
Western blot analysis as described before [64]. Briefly, protein
samples were separated on 10% SDS-PAGE gels and transferred
to PVDF membrane (GE Healthcare) using a wet transfer
apparatus (Invitrogen). Membranes were blocked in TBST buffer
(20 mM Tris, 150 mM NaCl, 0.1% Tween-20 pH 7.6) containing
5% non-fat dry milk for 1 hr at room temperature and then
incubated overnight with appropriate primary antibody at 4uC.
The membranes were washed three times, 15 minutes each with
TBST and incubated with HRP-conjugated goat-anti-mouse
(1:10,000) or goat anti-rabbit (1:10,000) secondary antibody in
TBST containing 5% non-fat dry milk for 1 hour at room
temperature with gentle agitation and were then washed three
times, 15 minutes each with TBST. The proteins were detected
using the chemiluminescence substrate (Pierce) and exposure to X-
ray film (Kodak). Protein bands on X-ray films were quantified by
using ImageJ software (rsb.info.nih.gov/ij).
Transfection of siRNAs and construction of stable cell
lines using lentivirus packaged with short hairpin RNAs
(shRNAs)
For siRNA transfection, cells were seeded at 56104 cells per
well in 24-well plates in growth medium without antibiotics. PKR
(target sequences: GUAAGGGAACUUUGCGAUA; GCGA-
GAAACUAGACAAAGU; CGACCUAACACAUCUGAAA;
CCACAUGAUAGGAGGUUUA) and DHX9 (target sequences:
GGAUUAAACUGCAAAUAUC; GGCUUUGGUUGUUGAA-
GUA; CAAACAACCUGCUAUCAUC; GUAAAUGAAC-
GUAUGCUGA) siRNAs used were ON-TARGETplus SMART
pool siRNA purchased from Thermo Scientific (Dharmacon). For
transfection, siRNA solution (50–100 nM final concentration/
well) was prepared in 50 ml Opti-MEM I Reduced serum medium
(Invitrogen). Lipofectamine RNAiMAX (Invitrogen) solution was
prepared in 50 ml Opti-MEM I Reduced serum medium and
incubated 5 min at room temperature. siRNA and lipofectamine
solutions were mixed and incubated for 20 min at room
temperature and added to the cells to make final volume of
500 ml and incubated at 37uC in a CO2 incubator. The knock
down was verified after 48–72 h of transfection. For infection, the
cells were infected with viruses after 48 h of post-transfection.
Lentivirus particles packaged with human PKR shRNAs or
control shRNAs were purchased from Snata Cruz Biotechnology
Inc. They were used independently to infect cells to construct
stable cell lines according to the manufacturer’s protocol. After
selection of puromycin (Sigma) antibiotic resistant cells, Western
blot analysis was performed to determine the level of PKR
knockdown.
Coimmunoprecipitation (co-IP) and mass spectrometry
of protein samples
For co-IP, cells were lysed using RIPA lysis buffer. The cleared
cell lysates after centrifugation for 15 min at 12,000 rpm at 4uC
were incubated with Pierce protein A/G agarose (Thermo
scientific) for pre-clearing. The agarose beads were removed by
centrifugation for 15 min at 12,000 rpm at 4uC. The supernatants
were incubated with a monoclonal anti-V5 antibody (Invitrogen)
for 1 h at 4uC and followed by incubation with protein A/G
agarose for over-night at 4uC. In some cases cell lysates were
treated with RNase A/T1 (Fermentas) or RNase V1 (Invitrogen)
overnight at 4uC. The agarose beads were pelleted by centrifu-
gation at 2,000 rpm for 2 minutes, washed four times with lysis
buffer and samples were then analyzed by Western blotting.
For mass spectrometry, protein samples from co-IP were
separated on a 12% SDS-PAGE gel by electrophoresis and
stained with mass spectrometry-compatible Coomassie blue
(SimplyBlue SafeStain; Invitrogen) according to the manufactur-
er’s protocol. Unique protein bands present in the
vMyxM029V5N virus infected samples compared to the controls
were dissected for trypsin digestion, followed by liquid chroma-
tography-tandem mass spectrometry analysis (done at the ICBR,
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UF, proteomic core). The results were searched against protein
database and then analyzed and displayed with matching
polypeptide sequences in the identified protein sequence using
Scaffold software (Proteome Software, Portland, OR).
Immunofluorescence microscopy
RK-13 cells grown on glass coverslips, were mock-infected or
infected with vMyxGFP or vMyxM029V5N for 3 h or 24 h at an
MOI of 5.0 or 0.1, respectively. After infection, cells were fixed in
4% paraformaldehyde in PBS for 10 min at room temperature
and permeabilized in 0.1% Triton X-100 in PBS for 10 min. Cells
were quenched in 0.1 M Glycine in PBS for 20 min and then
blocked in 1% BSA in PBS for 30 min. Cells were incubated with
an anti-V5 monoclonal antibody, followed by Texas Red-
conjugated goat anti-mouse antibody (Jackson ImmunoResearch
Laboratories). DNA in the nuclei and viral factory was stained
with 49,6-diamidino-2-phenylindole (DAPI). Images were captured
on a Leica laser scanning confocal microscope.
RNA purification and real-time PCR
Total RNA was purified from 106 cells plated in each well of a
six-well dish. The following day cells were infected with viruses. At
the given time points, cells were lysed with RLT buffer (Qiagen),
and total RNA was extracted using RNeasy kit (Qiagen).
Generally, 1–2 mg of total RNA was used to make cDNA.
Genomic DNA was removed from total RNA using DNA-free kit
(Ambion) according to the manufacturer’s recommendations.
Following the removal of genomic DNA, cDNA was prepared
using Superscript III reverse transcriptase (Invitrogen) [65]. PCR
amplification was performed for 35 cycles using the following
cycling conditions: 94u for 1 min, followed by 35 cycles of 94u for
30 seconds, 56u for 30 seconds, 72u for 1 min, and then a final
extension of 72u for 10 min. Forward and reverse primer pairs are
listed in supplementary Table 1. Lack of DNA contamination in
the RNA preparation was verified by PCR amplification in the
absence of reverse transcription.
Animal studies
New Zealand White rabbits were purchased from Charles River
Laboratories International. The animal study was approved by the
Institutional Animal Care and Usage Committee (IACUC) at the
University of Florida and studies were performed as described
before [66]. For virus injection, 1000 focus-forming units (FFU) of
the tested virus was resuspended in 100 ml of PBS and inoculated
intradermally in the left flank of each rabbit. Daily physical
examinations were conducted to evaluate rabbits condition by
monitoring respiration, weight, temperature, heart rate, lung sound,
food and water intake, urine and feces output, hydration status,
attitude, posture and indications of primary lesion and appearance
of secondary lesions. Based on the evaluations, the rabbits received
daily clinical score that ranged from 0 to 34 (the maximum score).
The animals were humanely euthanized when the clinical score
reached 26 to 34, had open mouth breathing due to respiratory
stress, orthopnea, cyanosis or no food and water intake for 48 h.
The animals that survived challenge with M029 mutant virus
infection, were re-challenged with a lethal dose of vMyx-Lau
(1000 FFU) by the intradermal route in the right flank of the animal.
Statistics
Data were expressed as means 6 SD and were analyzed by
paired t-test. Significant difference was accepted at p,0.05.
Supporting Information
Figure S1 MYXV M028 and M030 gene transcripts can
be detected from M029-defective virus infection. Total
RNA was extracted from vMyx-GFP, vMyx-M029ID and vMyx-
M029KO virus-infected RK13 cells after 24 h p.i. and subjected
to RT-PCR using specific primers for M028, M029, M030 and
rabbit GAPDH (as control). The amplified products were resolved
on a 1.5% agarose gel and the bands were visualized by SYBR
Green I nucleic acid gel stain (Invitrogen).
(TIF)
Figure S2 M029 protein interacts with human PKR via
dsRNA in virus-infected cells. HeLa cells were infected with
vMyx-M029V5N for 24 h, cell lysates were treated with RNase
V1 (10 u/ml) or RNase A/T1 at 4uC over-night and co-IP was
performed using mouse anti-V5 antibody. After Western transfer
the blot was probed with the indicated antibodies.
(TIF)
Figure S3 PKR protein interacts directly with DHX9 in
HeLa cells independent of dsRNA. Uninfected HeLa cell
lysates were treated with RNase V1 (10 u/ml) at 4uC over-night
and co-IP was performed using rabbit anti-DHX9 antibody. After
Western transfer the blot was probed with mouse anti-PKR and
anti-DHX9 antibodies.
(TIF)
Figure S4 MYXV early and late gene transcripts remain
unchanged in the absence of DHX9. THP1, shPKR-THP1
and shPKR-THP1 cells transfected with DHX9 siRNA were
infected with vMyx-GFP and vMyx-M029ID viruses for indicated
time points without (3 and 24) or with araC (24a). Total RNA was
extracted from these cells and subjected to RT-PCR using specific
primers for M-T7 (early gene), Serp-1 (late gene) and human
GAPDH (as control). The amplified products were resolved on a
1.5% agarose gel and the bands were visualized by SYBR Green I
nucleic acid gel stain.
(TIF)
Figure S5 Rabbit type I IFN restricts the replication of
M029-defective MYXV in rabbit cells. RK13 cells were
transfected with poly I:C (InvivoGen) overnight and the induced
supernatants were harvested for assay. A) RK13 cells were infected
with the indicated viruses with an MOI of 0.1 in the absence or
presence of the rabbit IFN containing supernatant. Fluorescence
images were taken after 48 h p.i. B) Virus was tittered from the
infected cell lysates after 48 h p.i. using RK13-E3 cells. * P,0.05
compared with untreated samples.
(TIF)
Table S1 Primers for RT-PCR.
(DOCX)
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